A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- Status
- RECRUITING
- Phase
- PHASE2
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
- Status
- COMPLETED
- Phase
- PHASE2
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
- Status
- COMPLETED
- Phase
- PHASE2
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2